Skip to main content
Future Medicine Co., Ltd. logo

Future Medicine Co., Ltd. — Investor Relations & Filings

Ticker · 341170 ISIN · KR7341170009 KO Manufacturing
Open in API
Filings indexed 93 across all filing types
Latest filing 2022-10-27 Report Publication Anno…
Country KR South Korea
Listing KO 341170

About Future Medicine Co., Ltd.

http://futuremedicine.co.kr/

Future Medicine Co., Ltd. is a new drug development company specializing in nucleoside-based synthetic drugs. The company focuses on creating therapeutics for diseases with high unmet medical needs, particularly in antiviral and anticancer applications. Its primary pipeline candidate, FM101, is an anti-inflammatory and anti-fibrotic agent being investigated for the treatment of conditions such as non-alcoholic steatohepatitis (NASH), diabetic nephropathy, and primary biliary cholangitis (PBC). The company has also conducted research and filed patents for therapeutics related to coronaviruses.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최결과
Report Publication Announcement Classification · 1% confidence The document is a formal notification regarding the results of an Investor Relations (IR) event held by Future Medicine. It lists the date, location, attendees, and agenda of the meeting. Since it is a short regulatory announcement confirming that an IR event took place and where the materials can be found, rather than the presentation itself, it falls under the category of a regulatory filing or announcement of report publication. Given the specific nature of the filing as a post-event disclosure, 'RNS' (Regulatory Filings) is the most appropriate classification.
2022-10-27 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 1% confidence The document is a short announcement regarding the scheduling and details of an upcoming Investor Relations (IR) event (기업설명회). It provides the date, location, purpose, and target audience for the meeting. Since it is an announcement of an event rather than the presentation materials themselves, and it is under 5,000 characters, it falls under the category of a regulatory filing announcement regarding an event.
2022-10-12 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically due to inheritance and account name changes) for the company 'Future Medicine'. This type of filing is a mandatory disclosure for significant shareholders crossing ownership thresholds, which falls under the 'Major Shareholding Notification' category.
2022-08-29 Korean
기타주요경영사항(자율공시)(비알콜성 지방간 질환(NAFLD) 또는 비알콜성 지방간염(NASH) 신약 개발을 위한 다국가 임상 2a상 시험계획(IND) 신청)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (Future Medicine) regarding a 'Major Management Matter' (기타 주요경영사항), specifically the filing of an Investigational New Drug (IND) application for a Phase 2a clinical trial. Since this is a specific regulatory announcement regarding clinical trial progress and does not fit into categories like financial reports, dividends, or M&A, it falls under the 'Regulatory Filings' (RNS) category as a general corporate disclosure.
2022-08-17 Korean
기타주요경영사항(자율공시)(국책과제 선정(A3 아데노신 수용체 조절제 FM101를 이용한 녹내장 치료제 개발 : 임상2a상 완료 및 2b상 개발))
Regulatory Filings Classification · 1% confidence The document is a 'Major Management Matter' (기타 주요경영사항) disclosure from Future Medicine regarding the selection of a government-funded research project for a glaucoma treatment. It details the project scope, funding, and timeline. Since it is a regulatory disclosure of a specific corporate event that does not fit into financial reporting, dividend announcements, or share transactions, it falls under the general regulatory filing category.
2022-08-11 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding status of an executive (Jeong Lak Shin) at Future Medicine. This type of filing is a standard regulatory requirement for reporting insider transactions or changes in ownership by company directors/executives, which corresponds to the 'Director's Dealing' category.
2022-08-03 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.